Myeloma Research NewsFirst Myeloma Patient in Study Treated with New CAR T-Cell Therapy bb21217Myeloma Research NewsThe therapy belongs to the class of CAR T-cell therapies, where the immune T-cells are collected from a patient and then re-engineered i… Continue reading
|
International Stem Cell Corporation announces breakthrough with 3D bioprinted liver tissue
3ders.org (blog) LPCs, ISCO explains, can be created from “any kind of pluripotent stem cells,” such as human embryonic, induced pluripotent, or parthenogenetic stem cells using the organization’s novel (and proprietary) differentiation system. “I’m excited to announce … |
FierceBiotech |
News of Note— A CAR–T for prostate cancer; targeting a faulty dementia gene; prompting cell suicide to treat leukemia
FierceBiotech San Diego-based Poseida Therapeutics is developing a chimeric antigen receptor T cell (CAR-T) therapy for prostate tumors that’s showing early promise in a particularly aggressive strain of the disease. Researchers at the company implanted human cell … |
FierceBiotech |
News of Note— A CAR–T for prostate cancer; targeting a faulty dementia gene; prompting cell suicide to treat leukemia
FierceBiotech San Diego-based Poseida Therapeutics is developing a chimeric antigen receptor T cell (CAR-T) therapy for prostate tumors that’s showing early promise in a particularly aggressive strain of the disease. Researchers at the company implanted human cell … |
|
US Stem Cell Inc (OTCMKTS:USRM) Could Be A Nice Recovery Play
Insider Financial US Stem Cell Inc (OTCMKTS:USRM) is a company that we have looked at on a few occasions over the last 12 months here at Insider Financial but it’s one that, over the last few months in particular, hasn’t had a particularly easy time in the markets. Investors Are Circling US Stem Cell, Inc. (OTCPK:USRM), What Do the Numbers Tell Us?MTNV ROE & Quant Signals in Focus For US Stem Cell, Inc. (OTCPK:USRM)Financial News Review |